Provided in the present invention is a sunitinib prodrug with a structure as shown by formula (I), whrerin R12, R13 are selected from H, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C8 cycloalkyl, C6-C10 aryl, a 4-15 membered heterocyclic ring and a 5-15 membered heteroaryl； R14 is selected from R', OR', SR' or N(R')2； and R' is selected from H, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C8 cycloalkyl, C6-C10 aryl, a 4-15 membered heterocyclic ring, a 5-15 membered heteroaryl, hydroxy C1-C6 alkyl, carboxyl C1-C6 alkyl, C1-C6 alkylamido and phosphoryl. The sunitinib prodrug provided in the present invention has better pharmacokinetics and pharmacodynamics, better safety and lower toxicity.
